<DOC>
	<DOCNO>NCT01945281</DOCNO>
	<brief_summary>The study evaluate safety , tolerability , efficacy caspofungin compare amphotericin B deoxycholate treatment invasive candidiasis neonates infant . The primary hypothesis test study caspofungin superior amphotericin B deoxycholate regard proportion participant fungal-free survival 2-week posttherapy follow-up visit .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Caspofungin Versus Amphotericin B Deoxycholate Treatment Invasive Candidiasis Neonates Infants ( MK-0991-064 )</brief_title>
	<detailed_description />
	<mesh_term>Candidiasis</mesh_term>
	<mesh_term>Candidiasis , Invasive</mesh_term>
	<mesh_term>Amphotericin B</mesh_term>
	<mesh_term>Liposomal amphotericin B</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Amphotericin B , deoxycholate drug combination</mesh_term>
	<mesh_term>Deoxycholic Acid</mesh_term>
	<criteria>Cultureconfirmed invasive Candida infection Candida disease limit oropharynx , esophagus , mucosal superficial skin surface Positive culture Candida sputum , bronchoalveolar lavage , catheter tip , previously place indwell nonvascular catheter drain Prosthetic device suspect site Candida infection Active coinfection nonCandida fungal organism Received &gt; 48 hour systemic antifungal treatment since positive Candida index culture collect therapy present episode invasive candidiasis Failed prior systemic antifungal therapy present episode invasive candidiasis Diagnosis acute hepatitis cirrhosis Scheduled anticipated receive rifampin systemic antifungal therapy study therapy History ( include participant 's mother ) allergy , hypersensitivity , serious reaction caspofungin member echinocandin class , amphotericin B deoxycholate member polyene class Severe congenital disorder know low immune response</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>3 Months</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>